Beyond APOE4: The Genetics of Personalized Prevention

How MTHFR and PEMT variants may reshape methylation, lipid transport, and phosphatidylcholine needs

I want to talk about something that doesn’t get enough attention in the APOE4 community.

We spend a lot of time discussing what to eat, which supplements to take, which labs to track. And that conversation matters. But underneath all of it is an assumption that rarely gets examined - that we’re all working with roughly the same biological machinery, just with an APOE4 variant layered on top.

We’re not.

And for some of us, that difference is significant enough to fundamentally change what an effective protocol actually looks like.

I know this because I’ve spent years building mine - and the more I’ve learned about my own genetics, the more I’ve understood why certain interventions matter more for me than standard recommendations would suggest, and why some things that work for others may not work the same way for me.

Here’s what I mean.

The Compounding Genetic Stack

Most people in this community know their APOE status. Fewer know their MTHFR status. And almost nobody is talking about PEMT.

I carry all three:

• APOE4/4 - homozygous, two copies

• MTHFR C677T - homozygous, two copies

• PEMT rs7946 T/T - homozygous, two copies

Each one individually warrants a specialized approach. Together, they create a compounding vulnerability that sits at the intersection of lipid transport, methylation, and phosphatidylcholine synthesis - three systems that are deeply interconnected and all critically relevant to brain health.

Let me walk through what each one actually means, and why the interaction between them matters more than any single variant in isolation.

APOE4/4 - You Already Know This One

If you’re reading this, you’re likely familiar with what APOE4 does. It impairs cholesterol recycling and lipid transport, particularly in the brain. It reduces amyloid clearance efficiency. It increases neuroinflammatory vulnerability.

What’s less often discussed is that APOE4’s impact on lipid transport means your brain has a harder time getting the phospholipids it needs to maintain neuronal membranes, support synaptic function, and clear metabolic waste.

This isn’t just a cardiovascular story. It’s a membrane integrity story. And that matters for everything that follows.

MTHFR C677T Homozygous - The Methylation Bottleneck

The MTHFR enzyme converts folate into its active form (5-methyltetrahydrofolate) which feeds the methylation cycle and ultimately supports the production of SAMe, your body’s primary methyl donor.

C677T homozygous reduces this enzyme’s activity by approximately 70-80%.

The practical consequences:

• Synthetic folic acid - found in fortified foods and many supplements - doesn’t just fail to help. It actively competes with and blocks what little conversion capacity you have. It works against you.

• SAMe production is compromised, affecting dozens of methylation-dependent processes throughout the body

• Homocysteine tends to accumulate - and elevated homocysteine is directly neurotoxic, independently associated with cognitive decline, and particularly concerning in APOE4 carriers

For anyone with this variant, the form of B vitamins in your supplement stack isn’t a minor detail. It’s foundational. Methylfolate - not folic acid. Methylcobalamin - not cyanocobalamin. This distinction matters enormously and most generic B complexes and most multi-vitamin blends get it wrong.

PEMT rs7946 T/T - The Liver Connection Most People Miss

PEMT stands for Phosphatidylethanolamine N-Methyltransferase. It’s an enzyme responsible for one of the body’s pathways for synthesizing phosphatidylcholine - primarily in the liver.

The rs7946 T/T variant (also called G523A, ‘A’ allele) reduces PEMT activity by approximately 30% in laboratory assays. The primary documented consequence in research is increased risk of non-alcoholic fatty liver disease - specifically because reduced PC synthesis in the liver impairs the liver’s ability to shuttle fats out of hepatic cells efficiently, leading to fat accumulation.

A few important caveats:

• The 30% reduction has been measured outside the human body - in vivo human experiments haven’t yet confirmed the precise mechanism

• The negative effect appears diet-dependent - observed primarily in individuals consuming high calorie Western dietary patterns

• It has not been consistently observed across all populations studied

Why it’s still relevant to this conversation:

The liver is the primary site of PC production for systemic distribution. If hepatic PC synthesis is impaired - even partially - it plausibly affects phospholipid availability more broadly. This is mechanistically interesting in the context of APOE4’s already impaired lipid transport, but I want to be clear: this is a plausible connection, not a confirmed one.

What I can say with more confidence is that my dietary pattern - low sugar, Mediterranean-leaning, lean body composition - is essentially the opposite of the high calorie Western diet that appears to trigger the negative PEMT expression. My liver enzymes are normal and triglycerides are low, suggesting this variant isn’t expressing negatively in my current context.

The practical implication I draw from carrying this variant - alongside the APOE4 and C677T combination - is that supporting PC availability through direct supplementation and dietary sources makes mechanistic sense as a precautionary measure. BodyBio PC, egg yolks, and choline-rich foods aren’t just generally good APOE4 choices. For someone with my genetic profile, they feel specifically warranted.

But I share this with appropriate humility - the science here is preliminary, and I’d encourage you to evaluate it accordingly rather than treating it as established fact.

What This Means Practically

Here’s what it means for my protocol specifically - shared not as prescription but as illustration of the principle:

BodyBio PC has become non-negotiable for me. Not just helpful - essential. Given impaired PEMT function, my endogenous phosphatidylcholine synthesis capacity may be less efficient. Delivering it directly via phospholipid complex bypasses the reduced efficiency pathway entirely. My Prodrome scan data shows this working - Total Phosphatidylcholines jumped from the 13th to 43rd percentile between annual scans following consistent PC supplementation.

Egg yolks matter more than standard recommendations suggest. Dietary phosphatidylcholine from egg yolks partially bypasses PEMT by delivering preformed PC directly. This isn’t about cholesterol anxiety - it’s about membrane substrate delivery. For me, three to four yolks daily feels biologically justified by this specific genetic context.

Methylated B vitamins are non-negotiable. Thorne Basic B or equivalent using 5-MTHF methylfolate and methylcobalamin. I personally avoid folic acid. Auditing every supplement in your stack for synthetic folic acid matters.

TMG (Trimethylglycine) supports both impaired pathways simultaneously. It provides an alternative methylation route that bypasses the impaired MTHFR enzyme, supporting homocysteine clearance and partially restoring methyl donor availability for whatever residual PEMT activity remains.

Homocysteine tracking becomes a primary biomarker. Not an afterthought. The C677T and PEMT combination creates compounding pressure on homocysteine elevation. Getting it below 7 and ideally toward 6 µmol/L is a meaningful target with direct neuroprotective implications.

Importantly, PEMT is not the body’s only phosphatidylcholine synthesis pathway. The CDP-choline (Kennedy) pathway also contributes significantly, but reduced PEMT efficiency may still increase reliance on dietary choline and preformed phosphatidylcholine.

The Bigger Point

Generic APOE4 protocols are built for the average APOE4 carrier. They’re useful starting points. But the APOE4 community is not genetically homogeneous, and the assumption that one protocol fits all is the same oversimplification we rightly criticize in mainstream medicine’s one-size-fits-all approach.

Knowing your APOE status is the beginning of personalization, not the end of it.

If you haven’t looked at MTHFR status, PEMT rs7946 or your phytosterol absorption genetics - and you’re finding that standard APOE4 protocols aren’t moving your biomarkers the way you’d expect - these variants are worth investigating.

Not to induce more anxiety. But because knowledge of the actual biological terrain you’re working with allows you to build something precise rather than generic.

The goal isn’t to follow someone else’s protocol. The goal is to understand your own biology deeply enough - it goes well beyond the APOE gene - to build one that actually fits.

That’s what I’m working on. And these three variants - APOE4/4, C677T, PEMT T/T — are a significant part of why my protocol looks the way it does.

---

As always - this is what I do and why. Not medical advice. Take it to your clinician, your functional medicine practitioner, or your own research process. The point is to give you better questions, not ready-made answers.

If you’ve tested for PEMT or MTHFR and found similar results, I’d love to hear about it in the comments. This is exactly the kind of community knowledge that helps all of us build more precise protocols.

---

Related resources worth exploring:

• Goodenowe’s plasmalogen research and ProdromeScan for phospholipid biomarker tracking

• Bredesen PreCODE framework for comprehensive APOE4 protocol building

• Husseine Yassine’s DHA transport research in APOE4 carriers

• MTHFR specific resources from Ben Lynch’s Dirty Genes framework